Completed PHASE3 INTERVENTIONAL NCT00209924

A Study of Gaboxadol in Primary Insomnia

A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Study of Gaboxadol in Primary Insomnia

Sponsor: H. Lundbeck A/S

Interventions Gaboxadol

Updated 6 times since 2017 Last updated: Mar 29, 2007 Started: Apr 30, 2004 Completion: Nov 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00209924, this PHASE3 trial focuses on Primary Insomnia and remains completed. Sponsored by H. Lundbeck A/S, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

H. Lundbeck A/S

Data source: H. Lundbeck A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gothenburg, Sweden